Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01980875
Title Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Gilead Sciences
Indications
Therapies
Age Groups: adult
Covered Countries USA | GBR | FRA | ESP | CAN | BEL | AUS


No variant requirements are available.